

Figure S1. Transfection efficiency of miR-17-5p mimics and inhibitor in macrophages as determined via reverse transcription-quantitative PCR. (A) Overexpression of miR-17-5p by miR-17-5p mimics. (B) Suppression of miR-17-5p by miR-17-5p inhibitor. Data are presented as the mean  $\pm$  SD. \*\*\*P<0.001 vs. NC group. miR, microRNA; NC, negative control.




Table SI. Clinical and biochemical characteristics of the study groups.

Variable	Health controls (n=30)	Patients with AS (n=30)	P-value
Age, years	57.37±11.56	64.17±9.56	0.016
Male, (%)	9 (30%)	13 (43.3%)	0.42
Smoke, (%)	2 (6.7%)	4 (13.3%)	0.67
Hypertension, (%)	0	15 (50%)	3x10 <sup>-5</sup>
Diabetes, (%)	0	16 (53.3%)	1.2x10 <sup>-5</sup>
T-CHO, mmol/l	4.15±1.36	5.39±1.31	0.001
HDL-cholesterol, mmol/l	1.34±0.46	1.37±0.40	0.76
LDL-cholesterol, mmol/l	2.84±1.17	2.79±0.94	0.86
Serum triglycerides, mmol/l	1.90±1.11	1.99±1.22	0.77
CRP, mg/l	1.18±1.55	3.02±4.16	0.029

AS, atherosclerosis; T-CHO, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein.